Joseph P. Colgan

Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource

Brian K. Link, Matthew J. Maurer, Grzegorz S. Nowakowski et al. · Journal of Clinical Oncology · 2013 · 326 citations · Full text

Comparison of a Second-Generation Combination Chemotherapeutic Regimen (m-BACOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin's Lymphoma

Leo I. Gordon, David Harrington, Janet Andersen et al. · New England Journal of Medicine · 1992 · 326 citations · Full text

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

Thomas E. Witzig, Craig B. Reeder, Betsy LaPlant et al. · Leukemia · 2010 · 298 citations · Full text

Bleomycin Pulmonary Toxicity Has a Negative Impact on the Outcome of Patients With Hodgkin's Lymphoma

William G. Martin, Kay M. Ristow, Thomas M. Habermann et al. · Journal of Clinical Oncology · 2005 · 297 citations · Full text

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

Patrick B. Johnston, David J. Inwards, Joseph P. Colgan et al. · American Journal of Hematology · 2010 · 219 citations

Hematological Malignancy, Lymphoid Neoplasia, Hodgkin Lymphoma +14